echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The 3rd round of tape procurement is about to hit, how should pharmaceutical companies deal with it?

    The 3rd round of tape procurement is about to hit, how should pharmaceutical companies deal with it?

    • Last Update: 2020-07-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "
    Pharmaceutical Network Market Analysis" Recently, the State Organization of Drug Centralized Procurement and Use of joint procurement office held an online drug centralized procurement symposium, for the third batch of national volume procurement to solicit the views of some enterprisesIn this regard, the industry believes that the third batch of drug centralized volume procurement is about to be put on the agenda, or will meet with you in JulySo in the face of the drug-in-quantity procurement of the large trend of price-for-quantity, drug companies should deal with it?seize the opportunity of bidding
    looking at the current band procurement, although the wave of price reduction around wave after wave, but for a large number of ordinary generic drugs, the current varieties involved in less, the impact is relatively controllable, market opportunities still existAfter all, 30-50 catalogs will become the norm, and it will take a long time to cover most of the medicinesTherefore, in this period of time, such as the record procurement, the sun hanging network, self-funded drug bargaining procurement and even in the single hospital point-to-point bargaining procurement, as well as professional chain pharmacies, DTP pharmacies will become an important opportunity for the development of pharmaceutical companiesPharmaceutical companies can further dilute the costs of enterprises and increase sales through multi-bid bidsrecognize the accelerated transformation of the medical reform situation
    in fact, the pharmaceutical policy is part of the layout of the major medical reform, from the aging of the population and external economic situation and other macro factors, the sustainable development of the health insurance fund is higher than the development of the pharmaceutical industry policy top designThe state is happy to see the pharmaceutical companies through industrial upgrading, to comply with the policy directionTherefore, in the country through the regularization of the purchase of the amount of health insurance control fees in the background, most pharmaceutical companies can do is to seize the time to carry out industrial upgrading and transformation, do not hope that miracles happen or can drill policy emptySimilarly, circulation companies and retail pharmacies need to consider the market pattern after volume purchases to compensate for the loss of prescription reflux hospitals and unit price losses resulting from their impactPharmaceutical marketing personnel should recognize the situation, and strive to enhance personal professional ability, expand multi-job work experience, it is possible not to be eliminated by the timesto the integrated development of raw material preparations
    at present, with the continuous deepening of the volume of procurement, many generic products are facing the "price" and "quantity" testDue to the high demand for production capacity and the risingofAPI, industrial pressure will be assigned to pharmaceutical companies at all stages, from api procurement to pharmaceutical production and distributionIn this context, the industry believes that with the integration of API development model of enterprises, the advantages will gradually highlightTherefore, some generic enterprises that do not have the direct transformation innovation ability can gradually reduce production costs by using "integration of raw material preparations" and can also reduce the impact of fluctuations in api prices on enterprisesIt is understood that many enterprises have now been api-preparation integrated development has been included in the company's long-term development strategy, and even many enterprises began to build new factories to cooperate with the developmentconclusion
    in general, China's drug, medical device stake procurement of normal operation has become a general trendWith the promotion of the belt procurement model and the national expansion, the common generic drugs without technical barriers will gradually return to the level of manufacturing profits, the high gross margin era of generic drugs is overIn the future, only pharmaceutical companies with research and development innovation capabilities and rich and stress-resistant product lines can have more opportunities and better development in an increasingly competitive market.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.